These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19684073)

  • 1. Trabectedin.
    Chuk MK; Balis FM; Fox E
    Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
    [No Abstract]   [Full Text] [Related]  

  • 2. Trabectedin and ovarian cancer: statistical trickery.
    Prescrire Int; 2011 Apr; 20(115):93. PubMed ID: 21648209
    [No Abstract]   [Full Text] [Related]  

  • 3. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
    Martin-Liberal J; Judson I
    Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
    Saponara M; Stacchiotti S; Gronchi A
    Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
    Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
    [No Abstract]   [Full Text] [Related]  

  • 7. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
    Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
    Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology of ovarian cancer and trabectedin mechanism of action.
    Ray-Coquard I
    Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.
    Liu SV; Zneimer S; Tahbaz A; Douer D
    Acta Haematol; 2011; 126(2):76-8. PubMed ID: 21502754
    [No Abstract]   [Full Text] [Related]  

  • 12. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
    Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
    Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
    Martinez-Trufero J; Alfaro J; Felipo F; Alvarez M; Madani J; Cebollero A
    Anticancer Drugs; 2010 Sep; 21(8):795-8. PubMed ID: 20622667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
    Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    D'Incalci M; Badri N; Galmarini CM; Allavena P
    Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
    Pick AM; Nystrom KK
    J Oncol Pharm Pract; 2010 Dec; 16(4):269-72. PubMed ID: 20015930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: Two Drugs for soft-tissue sarcoma.
    Med Lett Drugs Ther; 2016 May; 58(1494):e62. PubMed ID: 27148925
    [No Abstract]   [Full Text] [Related]  

  • 20. Trabectedin mechanism of action: what's new?
    D'Incalci M
    Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.